Search results for "transitional"

Changes in Students' Psychological Well-Being during Transition from Primary School to Lower Secondary School : A Person-Centered Approach

2019

This person-centered study examined the patterns and the dynamics of pattern change based on 1666 Finnish students' self-reported psychological well-being during the transition from primary school to lower secondary school. Moreover, we examined the stability in the profile memberships and the influence of changes in perceived support from teachers, families, and peers on changes in students' psychological well-being. Six student profiles were identified using the I-states-as-objects-analysis (ISOA) procedure: (a) High well-being profile; (b) Average well-being but low educational aspirations profile; (c) Low well-being profile; (d) Low well-being but high educational aspirations profile; (…

A phase I-II study on intravesical Gemcitabine in superficial bladder papillary tumors

2004

INTRODUCTION AND OBJECTIVE: The possible role of gemcitabine inintravesical therapy of superficial transitional cell carcinoma of the bladder (TCCB) has been suggested. The European Organization for Research and Treatment of Cancer Urological Group validated the use of papillary marker lesion left in the bladder after TUR as the best tool to measure the efficacy of a drug by intravesical route against TCCB. The rsults on 27 patients are herein presented. METHODS: Twenty-seven patients, with recurrent superficial TCCB (Ta-T1, G1-G2), were treated with intravesical gemcitabine for 1 to 3 papillary marker lesions (5-15 mm) left unreseacted after TUR. Twenty-one patients (78%) had recurrent tum…

Dataset from: Small-scale patches of detritus as habitat for invertebrates within a Zostera noltei meadow

2021

This dataset is related to "Small-scale patches of detritus as habitat for invertebrates within a Zostera noltei meadow" (Valentina Costa, Renato Chemello, Davide Iaciofano, Sabrina Lo Brutto, Francesca Rossi)

Hyperammonemic encephalopathy after urinary diversion. Diet therapy

2016

Is there a role for recombinant tumor necrosis factor alpha in the intravesical treatment of superficial bladder tumors?--a phase II study

1995

Clinical use of recombinant tumor necrosis factor-alpha is strongly limited by its severe toxicity, mainly cardiovascular, when systemically administered. Recent studies suggest that topical (intrapleural, intraperitoneal, intratumoral) administration is free of significant toxicity. Human recombinant tumor necrosis factor-alpha was administered intravesically, at a dose of 500 mg dissolved in 30 ml of phosphate buffer (pH7.6-7.8) plus 0.25% human albumin, weekly for two months to 18 patients with papillary transitional cell carcinoma of the bladder. Of the 15 evaluable patients, four (26%) achieved a complete response. Systemic and local tolerability were excellent. Int J Urol 1995;2:100-1…

Transitional cell carcinoma of the renal pelvis presenting as a renal abscess.

2002

We report on a 76-year-old woman who was diagnosed with a primary renal abscess of the left kidney. After percutaneous drainage, no clinical improvement was observed. Surgical exploration and nephrectomy were performed. The histologic evaluation revealed an unsuspected transitional cell carcinoma of the renal pelvis, which had been misinterpreted as a primary renal abscess. Malignancy must be considered as an underlying cause for the formation of a renal abscess, especially if no other predisposing factors such as diabetes mellitus or urinary stones are present.

Radical Cystectomy - Often Too Late?

1987

From 1967 to 1985, 246 cystectomies for treatment of transitional cell carcinoma of the urinary bladder were performed. Perioperative mortality decreased from 15% in the early years to 0% in 1985. Preoperative radiotherapy was not given. Patients who underwent cystectomy immediately following the diagnosis of invasive bladder carcinoma had a significantly better prognosis than those having cystectomy after recurrence of a transurethrally resected invasive carcinoma in spite of identical G and T criteria. A total of 26 patients who were cystectomized because of tumor recurrence after definitive radiotherapy (salvage cystectomy) represented the group with the worst prognosis: they had a 5-yea…

Lymphadenectomy in patients with transitional cell carcinoma of the urinary bladder; significance for staging and prognosis

2001

Objective  To determine the need to standardize the number and location of lymph nodes to be removed during radical cystectomy in patients with invasive bladder carcinoma. Patients and methods  The pelvic lymph nodes from 447 patients (mean age 62.8 years) who underwent radical cystectomy between 1986 and 1997 were evaluated. The number of lymph nodes was correlated with the depth of invasion of the primary tumour (pT), occurrence of nodal metastases, clinical outcome, the operating surgeons and the pathologists dissecting the nodes. Results  The clinical follow-up was available for 302 patients (mean follow-up 38.7 months). The mean (range) number of lymph nodes removed was 14.7 (1–46). Th…

Intravesical Treatment of Superficial Urinary Bladder Tumours with Adriamycin

1980

Personal experience resulted in the observation that intravesical Adriamycin (ADM) is effective in some patients with multiple or diffuse papillary bladder tumours. A review of the literature shows that similar results have been obtained elsewhere, especially in Japan and Sweden. The response rate was higher if single doses of at least 50 mg were employed. Intravesical instillations of ADM appear to be valuable also in the treatment of carcinoma in situ and in prophylactic treatment after transurethral resection (TUR) of papillary bladder tumours.

Results of conservative treatment (transurethral resection plus adjuvant intravesical chemotherapy) in patients with primary T1, G3 transitional cell…

1996

Objectives. To evaluate a selected population of 50 consecutive patients with primary T1, G3 bladder transitional cell carcinoma in the absence of carcinoma in situ (Tis) treated with a bladder-sparing approach. Methods. Between January 1983 and December 1992, all patients were treated by transurethral resection (TUR) plus adjuvant intravesical chemotherapy over 1 year. In most cases, doxorubicin, epirubicin, and mitomycin were used alone or in combination. Results. At a mean follow-up period of 52 months (range, 18 to 126), 16 of 50 patients (32%) showed a recurrent superficial tumor. The recurrent lesion was of Stage T1 in 11 (22%) cases, but was a T1, G3 tumor only in 5 cases (10%). In 2…